Treviso, February 12, 2025 – SolidWorld Group S.p.A., listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group, leader in the integration of advanced 3D digital solutions and artificial intelligence, for the industrial, biomedical and defense sectors, announces a significant milestone in the development of Bio3DPrinting.
Electrospider technology, a patented platform developed by Bio3DPrinting, a spin-off of the University of Pisa, has been cited in a scientific study recently published in Biomedical Materials, a peer-reviewed scientific journal published by IOP Publishing. The citation recognizes the technology’s explicit role within a publication validated by the scientific community, placing it within the scope of reference literature in the field of advanced biomanufacturing.
Specifically, the study led to the creation, through 3D bioprinting, of three-dimensional structures designed to reproduce the organization and properties of complex biological tissues, such as the anterior cruciate ligament of the knee, with the aim of supporting preclinical research and advanced experimentation. The bioprinted biological models in the study are technologically advanced models that demonstrate the feasibility of using a hybrid biofabrication process (i.e., combining different technologies and materials) to build tissues in biologically relevant contexts, in a repeatable and controlled manner, not only as an isolated experiment, but with concrete potential for use on a larger scale in preclinical research and tissue engineering.
In this context, Electrospider has played a central role thanks to its multifunctional print head, which allows multiple biofabrication techniques to be integrated into a single bioprinting process. This architecture allows materials with different functions (structural, supportive, and biomimetic) to be combined, resulting in more complex structures with a more realistic and controlled internal organization than traditional bioprinting systems.
This approach, combined with computational prediction—simulations that help predict how the structure will work once built—contributes to the development of biological models capable of more accurately reproducing the characteristics and functionality of native human tissues, improving the quality and reliability of experimental research.
From a scientific and healthcare perspective, the availability of more accurate biological models helps improve the quality of preclinical research, supporting more reliable studies and reducing the gap between laboratory experimentation and future applications. Looking ahead, this may translate into more effective tools for understanding diseases, evaluating new therapies, and developing solutions geared toward increasingly personalized medicine.
This result is part of Bio3DPrinting’s efforts to build a structured dialogue between research and industry by promoting proprietary technology platforms that support scientific innovation and contribute, over time, to improving the quality of care and, more generally, people’s quality of life.
“The mention of Electrospider in this scientific study represents an important step in the validation process of our technology,” said Aurora De Acutis, co-founder of Bio3DPrinting. “It demonstrates how our multiscale and multifunctional biofabrication ecosystem can be used in advanced research contexts and confirms the soundness of our approach in developing solutions that put advanced biofabrication technologies at the service of science.”
With this achievement, SolidWorld Group consolidates its long-term strategy in the biomedical sector, continuing to invest in the development of proprietary technologies and the construction of an ecosystem capable of connecting scientific research, industrial innovation, and social value, following a rigorous and progressive path.
***
SolidWorld Group S.p.A. listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group leader in the integration of advanced 3D digital solutions and artificial intelligence, serving strategic and next-generation industrial sectors. Founded in the early 2000s by engineer Roberto Rizzo, the Group drives the transformation of manufacturing companies toward “Factory 5.0” through proprietary software and hardware technologies that make production processes faster, more sustainable, and more efficient. Comprising 10 companies, 14 locations 3 tech hubs, and over 178 employees SolidWorld serves more than 10,000 clients. Key innovations include Electrospider, a 3D bioprinter capable of replicating human tissues and organs. As of December 31, 2024, the Group recorded a Value of Production equal to Eur 66,2 million and an EBITDA of Eur 6.5 million. www.solidworldgroup.it
CONTACTS
Investor Relations Manager
Elisabetta Cammarata
investor@solidworld.it
IR & Media Relations Advisor
Image Building Società Benefit
solidworld@imagebuilding.it – Tel. +39 02 89011300
